Clinical Trial Detail

NCT ID NCT01885897
Title IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Masonic Cancer Center, University of Minnesota
Indications

chronic myeloid leukemia

myeloid neoplasm

acute myeloid leukemia

chronic lymphocytic leukemia

acute lymphoblastic leukemia

lymphoma

Therapies

ALT-803

Age Groups: adult senior

No variant requirements are available.